The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, SARS Coronavirus, and Influenza A Virus
Open accessAbstract
Interferon-inducible transmembrane proteins 1, 2, and 3 (IFITM1, 2, and 3) are recently identified viral restriction factors that inhibit infection mediated by the influenza A virus (IAV) hemagglutinin (HA) protein. Here we show that IFITM proteins restricted infection mediated by the entry glycoproteins (GP(1,2)) of Marburg and Ebola filoviruses (MARV, EBOV). Consistent with these observations, interferon-β specifically restricted filovirus and IAV entry processes. IFITM proteins also inhibited replication of infectious MARV and EBOV. We observed distinct patterns of IFITM-mediated restriction: compared with IAV, the entry processes of MARV and EBOV were less restricted by IFITM3, but more restricted by IFITM1. Moreover, murine Ifitm5 and 6 did not restrict IAV, but efficiently inhibited filovirus entry. We further demonstrate that replication of infectious SARS coronavirus (SARS-CoV) and entry mediated by the SARS-CoV spike (S) protein are restricted by IFITM proteins. The profile of IFITM-mediated restriction of SARS-CoV was more similar to that of filoviruses than to IAV. Trypsin treatment of receptor-associated SARS-CoV pseudovirions, which bypasses their dependence on lysosomal cathepsin L, also bypassed IFITM-mediated restriction. However, IFITM proteins did not reduce cellular cathepsin activity or limit access of virions to acidic intracellular compartments. Our data indicate that IFITM-mediated restriction is localized to a late stage in the endocytic pathway. They further show that IFITM proteins differentially restrict the entry of a broad range of enveloped viruses, and modulate cellular tropism independently of viral receptor expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Self-citationReceptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin
Skehel, J. J., & Wiley, D. C. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.531 · Cited by 2,706
Brass, A. L., Huang, I.-C., Benita, Y., John, S. P., Krishnan, M. N., Feeley, E. M., Ryan, B. J., Weyer, J. L., van der Weyden, L., Fikrig, E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.12.017 · Cited by 1,269
Self-citationHarrison, S. C. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1456 · Cited by 1,190
Belouzard, S., Chu, V. C., & Whittaker, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809524106 · Cited by 1,073
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., & Bates, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505577102 · Cited by 1,052
Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection
Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P., & Cunningham, J. M. (2005) · Science · doi:10.1126/science.1110656 · Cited by 826
NEW EMBO MEMBERS' REVIEW: Lysosomal cysteine proteases: facts and opportunities
Turk, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4629 · Cited by 756
Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M., & Stark, G. R. (1984) · Cell · doi:10.1016/0092-8674(84)90270-8 · Cited by 718
Wong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 694
Self-citation
Cited by
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Self-citationImmunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
Human Coronavirus: Host-Pathogen Interaction
Fung, T. S., & Liu, D. X. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115759 · Cited by 960
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
The broad-spectrum antiviral functions of IFIT and IFITM proteins
Diamond, M. S., & Farzan, M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3344 · Cited by 849
Self-citationIFITM3 restricts the morbidity and mortality associated with influenza
The GenISIS Investigators, Everitt, A. R., The MOSAIC Investigators, Clare, S., Pertel, T., John, S. P., Wash, R. S., Smith, S. E., Chin, C. R., Feeley, E. M., et al. (2012) · Nature · doi:10.1038/nature10921 · Cited by 782
Self-citationImmune response, inflammation, and the clinical spectrum of COVID-19
García, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01441 · Cited by 739
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00908-w · Cited by 731
Emerging Pandemic Diseases: How We Got to COVID-19
Morens, D. M., & Fauci, A. S. (2020) · Cell · doi:10.1016/j.cell.2020.08.021 · Cited by 716
Human Coronaviruses: A Review of Virus–Host Interactions
Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 591
Interferon-inducible effector mechanisms in cell-autonomous immunity
MacMicking, J. D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3210 · Cited by 579
Bat-borne virus diversity, spillover and emergence
Letko, M., Seifert, S. N., Olival, K. J., Plowright, R. K., & Munster, V. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0394-z · Cited by 553
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Yuen, C.-K., Lam, J.-Y., Wong, W.-M., Mak, L.-F., Wang, X., Chu, H., Cai, J.-P., Jin, D.-Y., To, K. K.-W., Chan, J. F.-W., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780953 · Cited by 524
IFITM-Family Proteins: The Cell's First Line of Antiviral Defense
Bailey, C. C., Zhong, G., Huang, I.-C., & Farzan, M. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085537 · Cited by 467
Self-citationSyncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106267 · Cited by 462
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 415
IFITM3 Inhibits Influenza A Virus Infection by Preventing Cytosolic Entry
Feeley, E. M., Sims, J. S., John, S. P., Chin, C. R., Pertel, T., Chen, L.-M., Gaiha, G. D., Ryan, B. J., Donis, R. O., Elledge, S. J., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002337 · Cited by 387
Self-citationRNA Interference Functions as an Antiviral Immunity Mechanism in Mammals
Li, Y., Lu, J., Han, Y., Fan, X., & Ding, S.-W. (2013) · Science · doi:10.1126/science.1241911 · Cited by 365
IFITM Proteins Restrict Viral Membrane Hemifusion
Li, K., Markosyan, R. M., Zheng, Y.-M., Golfetto, O., Bungart, B., Li, M., Ding, S., He, Y., Liang, C., Lee, J. C., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003124 · Cited by 358
Bertram, S., Dijkman, R., Habjan, M., Heurich, A., Gierer, S., Glowacka, I., Welsch, K., Winkler, M., Schneider, H., Hofmann-Winkler, H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03372-12 · Cited by 350
The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
Amini-Bavil-Olyaee, S., Choi, Y. J., Lee, J. H., Shi, M., Huang, I.-C., Farzan, M., & Jung, J. U. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.03.006 · Cited by 348
Self-citationSyncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107405 · Cited by 333
Borghesan, M., Fafián-Labora, J., Eleftheriadou, O., Carpintero-Fernández, P., Paez-Ribes, M., Vizcay-Barrena, G., Swisa, A., Kolodkin-Gal, D., Ximénez-Embún, P., Lowe, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.095 · Cited by 315
“A similar response was observed using stable HFFF2 infected with a previously validated shRNA targeting IFITM3 (Huang et al., 2011) (Figures S7D and S7E).”
BackgroundDesai, T. M., Marin, M., Chin, C. R., Savidis, G., Brass, A. L., & Melikyan, G. B. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004048 · Cited by 326
Self-citationInterferon-stimulated genes: roles in viral pathogenesis
Schoggins, J. W. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.03.006 · Cited by 314
Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism
Park, J.-E., Li, K., Barlan, A., Fehr, A. R., Perlman, S., McCray, P. B., & Gallagher, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608147113 · Cited by 307
Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754293 · Cited by 293
Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response
Kindler, E., Thiel, V., & Weber, F. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.006 · Cited by 290
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections
Shen, L. W., Mao, H. J., Wu, Y. L., Tanaka, Y., & Zhang, W. (2017) · Biochimie · doi:10.1016/j.biochi.2017.07.016 · Cited by 285
Regulation of hepatic innate immunity by hepatitis C virus
Horner, S. M., & Gale, M. (2013) · Nature Medicine · doi:10.1038/nm.3253 · Cited by 278
Zhang, Y.-H., Zhao, Y., Li, N., Peng, Y.-C., Giannoulatou, E., Jin, R.-H., Yan, H.-P., Wu, H., Liu, J.-H., Liu, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms2433 · Cited by 265
Global absence and targeting of protective immune states in severe COVID-19
Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Chew, N. W., Cleary, S. J., Kushnoor, D., Reeder, G. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03234-7 · Cited by 256
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Zang, R., Case, J. B., Yutuc, E., Ma, X., Shen, S., Gomez Castro, M. F., Liu, Z., Zeng, Q., Zhao, H., Son, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012197117 · Cited by 240
IFITM Proteins Incorporated into HIV-1 Virions Impair Viral Fusion and Spread
Compton, A. A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang, C., Casartelli, N., & Schwartz, O. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.001 · Cited by 231
“Previous reports demonstrate that they block virus entry (Brass et al., 2009; Huang et al., 2011) at the level of virus-cell fusion by affecting the biophysical properties (Desai et al., 2014; Li et al., 2013) or composition (Amini-Bavil-Olyaee et al., 2013) of the cellular membranes in which they…”
Two-stepping through time: mammals and viruses
Meyerson, N. R., & Sawyer, S. L. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.03.006 · Cited by 133
Tartour, K., Nguyen, X.-N., Appourchaux, R., Assil, S., Barateau, V., Bloyet, L.-M., Burlaud Gaillard, J., Confort, M.-P., Escudero-Perez, B., Gruffat, H., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006610 · Cited by 69
Multifunctional role of exosomes in viral diseases: From transmission to diagnosis and therapy
Chaudhari, P., Ghate, V., Nampoothiri, M., & Lewis, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110325 · Cited by 72
IFITM5 mutations and osteogenesis imperfecta
Hanagata, N. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0667-1 · Cited by 38
Metadata
- Authors
- Huang, I.-C., Bailey, C. C., Weyer, J. L., Radoshitzky, S. R., Becker, M. M., Chiang, J. J., Brass, A. L., Ahmed, A. A., Chi, X., Dong, L., Longobardi, L. E., Boltz, D., Kuhn, J. H., Elledge, S. J., Bavari, S., Denison, M. R., Choe, H., & Farzan, M.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-06
- Volume
- 7
- Issue
- 1
- Pages
- e1001258
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2135264287
- Cited by
- 603
- References
- 25
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.